Arcus Biosciences completes Phase 1/1b trial of AB801 in advanced malignancies
The 29-participant study tested AB801 alone and with docetaxel, reaching primary completion in April 2026.
Arcus Biosciences closed out its early-stage work on AB801 for the week ending October 9, 2026.
- AB801 (NCT06120075, "ARC-27") is a Phase 1/1b trial sponsored by Arcus Biosciences that evaluated safety and tolerability of AB801 given alone and in combination therapy in patients with advanced malignancies, aiming to identify a recommended dose for further study1. The trial is listed as completed, with a start date of January 19, 2024 and primary completion on April 29, 20261, and enrolled 29 participants1. The design included a dose expansion cohort in which NSCLC patients received AB801 orally alongside intravenous docetaxel1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.